Europe Blood Screening Market Size is Estimated to Attain $1.17 Billion by 2025: Grand View Research, Inc.

San Francisco, United States, 2019-May-24 — /EPR Network/ —

The Europe Blood Screening Market size is expected to reach USD 1.17 billion by 2025 according to a new report by Grand View Research, Inc. The market is expected to record a CAGR of 7.7% during the forecast period. Increasing number of blood transfusion processes performed along with stringent regulations in Europe mandating screening tests, such as NAT for testing HIV, HBV, and HCV, is contributing to the market growth.

Moreover, growth in the overall number of complex surgeries that require a large amount of blood and blood products along with rising cases of road accidents is expected to drive the market further. Additionally, import of products through contract agreements and development in the product technology by manufacturers of blood screening reagents and instruments are contributing to market expansion in the region.

For example, DiaSystem Scandinavia AB signed a distribution agreement with SNIBE, an Asian immunology test producer that focuses on immunoassay analyzers based on CLIA technology. DiaSystem specializes in the production and supply of reagents used in chemistry and immunoturbidimetry. This agreement has provided the former company with automated chemiluminescence instrument delivering a complete analytical system in areas, such as thyroid, renal function, hepatitis, and hepatic fibrosis.

To request a sample copy or view summary of this report, click the link below: 
https://www.grandviewresearch.com/industry-analysis/europe-blood-screening-market

Further key findings from the study suggest:

• NAT led the technology segment in 2017 owing to a regulatory obligation for mandatory NAT screening for all blood donations.
• On the basis of product, reagents led the Europe blood screening market in 2017
• Germany held a majority of the market share in 2017 due to large number of blood donors.
• Moreover, stringent regulations in the country for screening of donations also contributed to its growth. The Paul-Ehrlich-Institut, a medical regulatory body in Germany, mandates NAT testing for HCV and HIV for all blood donations.
• Roche Diagnostics; Bio-Rad Laboratories, Inc.; Siemens Healthcare GmbH; Grifols, S.A.; Becton, Dickinson and Company; Agilent Technologies; Thermo Fisher Scientific, Inc.; and Danaher Corp. are some of the key companies operating in this market.

Browse More Reports in Clinical Diagnostics Industry:

• Clot Management Devices Market
• Intravenous (IV) Solutions Market

Grand View Research has segmented the Europe blood screening market on the basis of technology, product, and country:

Europe Blood Screening Technology Outlook (Revenue, USD Million, 2014 – 2025)

• Nucleic Acid Amplification Test (NAT)
• Enzyme-Linked Immunosorbent Assay (ELISA)
• Chemiluminescence Immunoassay (CLIA)
• Next Generation Sequencing (NGS)
• Western Blotting

Europe Blood Screening Product Outlook (Revenue, USD Million, 2014 – 2025)

• Reagents
• Instruments

Europe Blood Screening Country Outlook (Revenue, USD Million, 2014 – 2025)

• U.K.
• Germany
• France
• Italy
• Spain